ARWR - アロ―ヘッド・リサ―チ (Arrowhead Pharmaceuticals Inc.) アロ―ヘッド・リサ―チ

 ARWRのチャート


 ARWRの企業情報

symbol ARWR
会社名 Arrowhead Research Corp (アロ―ヘッド・リサ―チ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アローヘッド・ファーマシューティカル(Arrowhead Pharmaceuticals Inc)(旧名:Arrowhead Research Corporation)は生物医薬品会社である。同社はRNA干渉(RNAi)治療法の開発に従事する。同社の製品は、ARC-520、ARC-521、ARC-AAT、ARC-F12、ARC-HIF2及びARC-LPAを含む。ARC-520は、慢性B型肝炎ウイルス(HBV)感染の治療に設計される。ARC-AATは、α-1アンチトリプシン欠損症(AATD)に関連肝疾患の治療のためRNAiベースの治療薬を含むアンロック核酸塩基アナログである。ダイナミック・ポリコンジュゲート・プラットフォームは、ターゲット遺伝子ノックダウンの高レベルを促進するRNAiデリバリシステムである。ARC-F12は、遺伝性血管浮腫および血栓塞栓性疾患のために予防的治療を提供するファクター12の産生を削減するように設計されるRNAiベースの治療である。ARC-LPAは、アポリポタンパク質Aの産生を減少させるように設計されるRNAiベースの治療である。ARC-HIF2は、低酸素誘導因子2aの産生を減少ために設計されるRNAiベースの治療である。   アロ―ヘッド・リサ―チは、米国のバイオ医薬品会社。疾患を引き起こす遺伝子をRNA干渉に基づき効率的に鎮め、難治性疾患を治療する薬剤を開発。主要製品は、慢性B型肝炎の治療のためにB型肝炎ウイルスを対象とするRNA干渉基盤の治療薬ARC-520である。本社はカリフォルニア州パサディナ。   Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing.
本社所在地 225 S. Lake Avenue Suite 1050 Pasadena CA 91101 USA
代表者氏名 Douglass B. Given ダグラスB.ギブン
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 626-304-3400
設立年月日 32782
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 104人
url www.arrowheadresearch.com
nasdaq_url https://www.nasdaq.com/symbol/arwr
adr_tso
EBITDA EBITDA(百万ドル) -50.39190
終値(lastsale) 13.75
時価総額(marketcap) 1210318298.75
時価総額 時価総額(百万ドル) 1211.198
売上高 売上高(百万ドル) 13.60112
企業価値(EV) 企業価値(EV)(百万ドル) 1153.09644
当期純利益 当期純利益(百万ドル) -54.42110
決算概要 決算概要 BRIEF: For the nine months ended 30 June 2018 Arrowhead Pharmaceuticals Inc revenues decreased 78% to $4.9M. Net loss increased 85% to $43.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development increase of 58% to $37M (expense) General and Administrative increase from $5.3M to $12.7M (expense).

 ARWRのテクニカル分析


 ARWRのニュース

   Arrowhead Pharma favored at H.C. Wainwright despite trial pause  2021/07/03 23:22:00 Seeking Alpha
   Here''s Why Arrowhead Pharmaceuticals Stock Is Getting Hammered Today  2021/07/02 16:18:27 The Motley Fool
A paused clinical trial with an important asset wasn''t what investors wanted to hear today.
   Arrowhead Pharmaceuticals Pauses Test of its Cystic Fibrosis Treatment  2021/07/02 14:29:16 The Street
Arrowhead''s move comes after a toxicology study in rats contained unexpected signals of local lung inflammation, the company says.
   Arrowhead rocked by animal tox issues again, hitting the pause button on RNAi study in cystic fibrosis  2021/07/02 14:24:12 Endpoints News
Arrowhead Pharmaceuticals faced a reckoning back in 2016 when it was forced to scrap its entire clinical pipeline after reporting deaths in a non-human primate toxicology study. Now, years later and with a different delivery vehicle for its RNAi drugs, Arrowhead faces animal tox issues again in what could be
   Mid-Day Market Update: Dow Surges Over 100 Points; Arrowhead Pharmaceuticals Shares Plummet  2021/07/02 12:18:00 Benzinga
Midway through trading Friday, the Dow traded up 0.33% to 34,747.45 while the NASDAQ rose 0.50% to 14,594.85. The S&P also rose, gaining 0.47% to
   B.Riley Financial Stick to Their Buy Rating for Arrowhead Pharmaceuticals By Investing.com  2021/03/18 15:05:10 Investing.com
B.Riley Financial Stick to Their Buy Rating for Arrowhead Pharmaceuticals
   Hereditary Angioedema Market to Demonstrates a Spectacular Growth with CSL Behring, Shire Plc., Pharming Healthcare, Inc., BioCryst Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Adverum Biotechnologies  2021/03/18 06:37:38 OpenPR
Hereditary angioedema (HAE) is characterized by acute skin and mucosal edema caused by an autosomal dominant mutation of the genes. The current treatments of the condition include the HAE drugs which can be administered intravenously, subcutaneously or taken orally. The
   Arrowhead Pharmaceuticals Files IND to Begin Phase 2b Study of ARO-APOC3 in Patients with Severe Hypertriglyceridemia  2021/03/01 12:30:00 Business Wire
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead submitted an IND to the U.S. Food and Drug Administration for ARO-APOC3, an RNAi therapeutic for hypertriglyceridemia
   Global Hepatitis B Virus (HBV) Market Report 2021-2030 Featuring Key players | Johnson & Johnson, Merck and Co, Bristol-Myers Squibb, Gilead Sciences, Arrowhead Pharmaceuticals, Arbutus Pharma  2021/02/24 21:15:00 PR Newswire
DUBLIN, Feb. 24, 2021 /PRNewswire/ -- The "Global Hepatitis B Virus (HBV) Market: 10 Year Demand Forecast & Impact of COVID-19 (2021-2030)" report has been added to ResearchAndMarkets.com's offering. The global hepatitis B virus (HBV) market is expected to reach US$35.63 billion in 2030,…
   FXNEWS24 |Arrowhead Pharmaceuticals Reaches Analyst Target Price | UK Forex Reviews  2021/02/22 14:32:50 FXNews24
Arrowhead Pharmaceuticals Reaches Analyst Target Price | UK Stocks, Forex, Commodities, Crypto, Live Market News- Daily Forex News
   Arrowhead Pharmaceuticals Files IND for Phase 2b Study of ARO-ANG3 for Treatment of Mixed Dyslipidemia  2021/01/25 12:30:00 Business Wire
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead files IND for ARO-ANG3 to start Phase 2b study in patients with mixed dyslipidemia
   Arrowhead Pharmaceuticals to Webcast Fiscal 2021 First Quarter Results  2021/01/19 21:00:00 Business Wire
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead to release earnings and hold conference call on February 4 2021
   Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CFO Sells $1,056,338.76 in Stock  2021/01/16 09:51:15 Watchlist News
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CFO Kenneth Allen Myszkowski sold 13,038 shares of the company’s stock in a transaction on Tuesday, January 12th. The shares were sold at an average price of $81.02, for a total transaction of $1,056,338.76. Following the sale, the chief financial officer now owns 445,446 shares of the company’s stock, valued at […]
   B.Riley Financial Stick to Their Buy Rating for Arrowhead Pharmaceuticals By Investing.com  2021/01/12 20:36:13 Investing.com
B.Riley Financial Stick to Their Buy Rating for Arrowhead Pharmaceuticals
   Insider Selling: Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CFO Sells 30,625 Shares of Stock  2021/01/11 09:12:47 Watchlist News
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CFO Kenneth Allen Myszkowski sold 30,625 shares of the company’s stock in a transaction on Wednesday, January 6th. The stock was sold at an average price of $72.44, for a total transaction of $2,218,475.00. Following the completion of the transaction, the chief financial officer now directly owns 486,568 shares of the […]

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アロ―ヘッド・リサ―チ ARWR Arrowhead Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)